Prescient Therapeutics (PTX)
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded May 22, 1986 and is headquartered in Perth, Australia.
|Market Price at 13-12-2017||$0.07|
|Price to Earnings Ratio||-4.35|
|Market Capitalisation||$14.37 (million)|
|Return on Equity (ROE)||-21.73%|